Tastemaker Acquisition Corp
Change company Symbol lookup
Select an option...
TMKR Tastemaker Acquisition Corp
SPY SPDR® S&P 500 ETF Trust
STOR STORE Capital Corp
PIPP^ Pine Island Acquisition Corp
PEP PepsiCo Inc
$NASI5000LMN NASDAQ Asia Cnsmr Svcs Large Mid Cap
PNM PNM Resources Inc
CBLAQ CBL & Associates Properties Inc
APLE Apple Hospitality REIT Inc
MET MetLife Inc
Go

Company profile

Tastemaker Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses. The Company has not selected any specific business combination target and may pursue an initial business combination target in any industry or geographic region. The Company is not engaged in any business and has not generated any revenue.

Closing Price
$9.86
Day's Change
-0.01 (-0.10%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.90
Day's Low
9.78
Volume
128,131

EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen

5:00 am ET January 13, 2021 (PR Newswire) Print

EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization. In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies. Amgen is a world leader in the treatment of autoimmune disorders, with a portfolio that includes both innovative medicines, including Otezla(R) and Enbrel(R), and biosimilar products, such as AMGEVITA(R) (a biosimilar to Humira(R)) and AVSOLA(R) (a biosimilar to Remicade(R)).

EVOQ Therapeutics today announced a license and collaboration agreement with Amgen.

About EVOQ TherapeuticsEVOQ Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens for recognition by the immune system. www.evoqtherapeutics.com

https://c212.net/c/img/favicon.png?sn=NY46318&sd=2021-01-13

View original content:http://www.prnewswire.com/news-releases/evoq-therapeutics-announces-a-license-and-collaboration-agreement-with-amgen-301207118.html

SOURCE EVOQ Therapeutics

https://rt.prnewswire.com/rt.gif?NewsItemId=NY46318&Transmission_Id=202101130500PR_NEWS_USPR_____NY46318&DateId=20210113

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.